Qingyang Lyu holds a PhD in pharmacy and pharmacology from the University of Hong Kong, with research expertise in drug delivery, gene editing, and cancer immunotherapy. She also earned a master’s degree in medical sciences and a bachelor’s degree in pharmacy, consistently ranking in the top 10% of her academic cohorts. Qingyang has contributed to eight high-impact publications, focusing on innovative drug delivery systems and anti-cancer therapies. She is passionate about advancing healthcare solutions through cutting-edge genome editing and translational research.